IL98205A - Type ii interleukin-1 receptors - Google Patents

Type ii interleukin-1 receptors

Info

Publication number
IL98205A
IL98205A IL98205A IL9820591A IL98205A IL 98205 A IL98205 A IL 98205A IL 98205 A IL98205 A IL 98205A IL 9820591 A IL9820591 A IL 9820591A IL 98205 A IL98205 A IL 98205A
Authority
IL
Israel
Prior art keywords
type
dna
seq
amino acid
cells
Prior art date
Application number
IL98205A
Other languages
English (en)
Other versions
IL98205A0 (en
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of IL98205A0 publication Critical patent/IL98205A0/xx
Publication of IL98205A publication Critical patent/IL98205A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL98205A 1990-06-05 1991-05-21 Type ii interleukin-1 receptors IL98205A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53419390A 1990-06-05 1990-06-05
US57357690A 1990-08-24 1990-08-24
US62707190A 1990-12-13 1990-12-13

Publications (2)

Publication Number Publication Date
IL98205A0 IL98205A0 (en) 1992-06-21
IL98205A true IL98205A (en) 1998-01-04

Family

ID=27415141

Family Applications (1)

Application Number Title Priority Date Filing Date
IL98205A IL98205A (en) 1990-06-05 1991-05-21 Type ii interleukin-1 receptors

Country Status (12)

Country Link
US (1) US20030060616A1 (ja)
EP (1) EP0460846B1 (ja)
JP (2) JP3155024B2 (ja)
AT (1) ATE213743T1 (ja)
AU (1) AU651596B2 (ja)
DE (1) DE69132937T2 (ja)
DK (1) DK0460846T3 (ja)
ES (1) ES2172502T3 (ja)
IE (1) IE911771A1 (ja)
IL (1) IL98205A (ja)
NZ (1) NZ238255A (ja)
WO (1) WO1991018982A1 (ja)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5470730A (en) * 1990-09-28 1995-11-28 Immunex Method for producing TH -independent cytotoxic T lymphocytes
ES2137933T3 (es) * 1990-09-28 2000-01-01 Immunex Corp Metodo para producir linfocitos t citotoxicos independientes de th.
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5538863A (en) * 1993-07-01 1996-07-23 Immunex Corporation Expression system comprising mutant yeast strain and expression vector encoding synthetic signal peptide
AU729873B2 (en) * 1993-12-14 2001-02-15 University Of Pittsburgh Systemic gene treatment of connective tissue diseases
AU690743B2 (en) * 1994-09-05 1998-04-30 Walter And Eliza Hall Institute Of Medical Research, The A novel haemopoietin receptor
ES2316149T3 (es) 1994-09-05 2009-04-01 The Walter And Eliza Hall Institute Of Medical Research Un nuevo receptor de hemopoyetina.
KR100510234B1 (ko) 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
DK1105485T3 (da) 1998-08-21 2006-10-30 Immunex Corp Human IL-1-epsilon-DNA og polypeptider
EP1939297A1 (en) 1998-09-24 2008-07-02 Pharmacia & Upjohn Company LLC Alzheimer's disease secretase
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6693172B1 (en) 1999-05-27 2004-02-17 Pharmacia And Upjohn Company Double mutant alpha-7 nicotinic acetylcholine receptor
US6455290B1 (en) 1999-07-09 2002-09-24 Pharmacia Italia S.P.A. Tankyrase homolog protein (THP), nucleic acids, and methods related to the same
US6835546B1 (en) 1999-10-22 2004-12-28 Pharmacia & Upjohn Company Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
US6498026B2 (en) 2000-02-25 2002-12-24 Hercules Incorporated Variant galactose oxidase, nucleic acid encoding same, and methods of using same
US6734005B2 (en) 2000-05-22 2004-05-11 Pharmacia & Upjohn Company Matrix metalloproteinases
US7259244B2 (en) 2000-06-16 2007-08-21 Nerviano Medical Sciences S.R.L. Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
EP1307551A2 (en) 2000-07-05 2003-05-07 PHARMACIA & UPJOHN COMPANY Human ion channels
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US20030049255A1 (en) * 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
MXPA04003057A (es) 2001-10-04 2005-06-20 Immunex Corp Proteina 4 de enlace ul16.
JP2005521401A (ja) 2002-03-27 2005-07-21 イミュネックス・コーポレーション ポリペプチド産生を増加させる方法
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
EP1648935A2 (en) 2003-07-25 2006-04-26 Amgen Inc. Antagonists and agonists of ldcam and methods of use
WO2005087801A1 (en) 2004-03-05 2005-09-22 The Board Of Trustees Of The University Of Illinois Peptide carrier for drug delivery
US7319015B2 (en) 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
US7582442B2 (en) 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
EP1753864A2 (en) 2004-04-14 2007-02-21 Monell Chemical Senses Center Taste receptors of the t1r family from domestic dog
CA2564769C (en) 2004-04-23 2013-12-17 Pharmacia & Upjohn Company Llc Cellular permissivity factor for viruses, and uses thereof
ATE432353T1 (de) * 2004-07-27 2009-06-15 Riken Vektor zur expression von humaner n-deacetylase/n-sulfotransferase 2
KR20070009269A (ko) 2005-07-15 2007-01-18 한국생명공학연구원 재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
BRPI0716762A2 (pt) 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
EP2500416A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
NO2188313T3 (ja) 2007-08-21 2018-03-31
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
JP2009183176A (ja) * 2008-02-05 2009-08-20 Univ Of Tokyo Ｉｌ−１タイプｉｉレセプター遺伝子の欠損変異体マウス
GB0803076D0 (en) 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
JP2011526916A (ja) 2008-06-30 2011-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 全身性紅斑性狼瘡を同定および処置するための診断標的および治療標的としてのリソソームホスホリパーゼａ２（ｌｐｌａ２）活性
WO2010024927A2 (en) 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
JP5524977B2 (ja) 2008-12-04 2014-06-18 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 高分泌性蛋白質のスクリーニングおよび組換え蛋白質の生産のための融合パートナーとしてのその用途
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US8277651B2 (en) 2009-03-13 2012-10-02 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
WO2010133662A1 (en) 2009-05-20 2010-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-17 polypeptides for use in the prevention or treatment of atherosclerosis
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2501398A1 (en) 2009-11-06 2012-09-26 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of atherosclerosis
CA2780542C (en) 2009-11-13 2020-03-24 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2525806B1 (en) 2010-01-20 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Angiopoietin-like-protein-4 (ANGPTL4) for the preservation of vascular endothelial-cell barrier integrity
JP2013528360A (ja) 2010-04-09 2013-07-11 アムジェン インコーポレイテッド Ｂｔｎｌ９タンパク質、核酸および抗体ならびにそれらの使用
AU2011239689A1 (en) 2010-04-15 2012-11-08 Amgen Inc. Human FGF receptor and beta-Klotho binding proteins
WO2012019160A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
US20130195863A1 (en) 2010-09-28 2013-08-01 Philippe Clezardin Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases
US20140105898A1 (en) 2011-02-28 2014-04-17 Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo Apoptosis-inducing molecules and uses therefor
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
JP2014517832A (ja) 2011-05-10 2014-07-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 自己免疫疾患を治療するための方法及び医薬組成物
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2013006479A2 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
WO2013009971A1 (en) 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Detection and screening method and materials useful in performance thereof
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20140315187A1 (en) 2011-09-02 2014-10-23 Amgen Inc. Pharmaceutical Product and Method of Analysing Light Exposure of a Pharmaceutical Product
UA118332C2 (uk) 2011-09-22 2019-01-10 Емджен Інк. Білок, що зв'язує антиген cd27l
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
EP2785365B1 (en) 2011-11-28 2017-07-19 Institut National de la Sante et de la Recherche Medicale (INSERM) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
CN104220460A (zh) 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
KR101932697B1 (ko) 2012-04-27 2019-03-21 노보 노르디스크 에이/에스 사람 cd30 리간드 항원 결합 단백질
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
WO2013182650A1 (en) 2012-06-06 2013-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of cancer
CA2878400A1 (en) 2012-07-19 2014-01-23 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2013354937B2 (en) 2012-12-07 2019-09-19 North Carolina State University Beta-hexosyl-transferases and uses thereof
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
EP3395423B1 (en) 2013-03-14 2023-09-20 Amgen Inc. Removal of leaked affinity purification ligand
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
CA2904337A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
ES2770976T3 (es) 2013-03-15 2020-07-06 Amgen Inc Anticuerpos PAC1 humanos
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
NZ713636A (en) 2013-05-30 2022-07-01 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015048272A1 (en) 2013-09-25 2015-04-02 Amgen Inc. V-c-fc-v-c antibody
AU2014342232B2 (en) 2013-10-31 2017-12-21 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
WO2015086727A2 (en) 2013-12-11 2015-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method for patients suffering of a cancer
JP6732660B2 (ja) 2014-01-13 2020-07-29 アムジエン・インコーポレーテツド 組換えタンパク質の高マンノースグリコフォーム含有量を操作するためのオルニチン代謝の調節
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
KR102410393B1 (ko) 2014-01-29 2022-06-16 암젠 인크 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
RU2019119862A (ru) 2014-02-20 2019-07-15 Аллерган, Инк. Антитела к компоненту комплемента c5
SG11201606983SA (en) 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
JP6695814B2 (ja) 2014-06-04 2020-05-20 アムジエン・インコーポレーテツド 哺乳類細胞培養物を回収するための方法
AU2015318008B2 (en) 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
CA2968372A1 (en) 2014-11-19 2016-05-26 Amgen Inc. Quantitation of glycan moiety in recombinant glycoproteins
EA036178B1 (ru) 2014-12-01 2020-10-09 Эмджен Инк. Процесс контроля уровня содержания гликанов в составе гликопротеинов
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
US10851144B2 (en) 2015-04-10 2020-12-01 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
MA42821A (fr) 2015-09-15 2018-07-25 Amgen Inc Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
JP7010812B2 (ja) 2015-09-22 2022-02-10 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質の発現
JP6983772B2 (ja) 2015-11-02 2021-12-17 ジェネンテック， インコーポレイテッド タンパク質のフコシル化及び脱フコシル化形態の作製方法
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
EP3808764A1 (en) 2016-05-04 2021-04-21 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
EP3487867A2 (en) 2016-07-22 2019-05-29 Amgen Inc. Methods of purifying fc-containing proteins
CA3043528A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
AU2018206279B2 (en) 2017-01-06 2020-09-03 Abl Bio Inc. Anti-alpha-syn antibody and use thereof
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
KR20200019122A (ko) 2017-06-20 2020-02-21 암젠 인크 Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
WO2019028382A1 (en) 2017-08-04 2019-02-07 Amgen Inc. CYS-MABS CONJUGATION METHOD
TWI831762B (zh) 2018-01-12 2024-02-11 美商安進公司 Pac1抗體及其用途
JP2022502454A (ja) 2018-10-04 2022-01-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 認知機能を回復又は改善するための方法
KR20210101270A (ko) 2018-12-10 2021-08-18 암젠 인크 돌연변이 피기백 트랜스포사제
TW202110877A (zh) 2019-05-30 2021-03-16 美商安進公司 工程改造鉸鏈區以驅動抗體二聚化
CA3143524A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
EP4385573A2 (en) 2019-08-13 2024-06-19 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
TW202132340A (zh) 2019-11-04 2021-09-01 美商安進公司 治療白血病之方法
AU2020380379A1 (en) 2019-11-08 2022-05-26 Amgen Inc. Engineering charge pair mutations for pairing of hetero-IgG molecules
WO2021102049A1 (en) 2019-11-19 2021-05-27 Amgen Inc. Novel multispecific antibody format
CA3162705A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
IL293640A (en) 2019-12-20 2022-08-01 Amgen Inc CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
EP4200338A1 (en) 2020-08-20 2023-06-28 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
JP2023544769A (ja) 2020-10-07 2023-10-25 アムジエン・インコーポレーテツド 多重特異性抗体の構築のためのビルディングブロックの合理的選択
TW202233660A (zh) 2020-10-30 2022-09-01 美商安進公司 過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
WO2022103773A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
JP2024515301A (ja) 2021-04-20 2024-04-08 アムジエン・インコーポレーテツド 多重特異性及び一価のｉｇｇ分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
US20240209115A1 (en) 2021-04-29 2024-06-27 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
MX2023014680A (es) 2021-06-10 2024-01-12 Amgen Inc Variantes genomodificadas de la nrg-1 con una selectividad mejorada frente al erbb4 pero no frente al erbb3.
TW202328442A (zh) 2021-09-10 2023-07-16 美商安進公司 平臺宿主對ｉｇｆ—培養基之適應
CA3241882A1 (en) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023172965A1 (en) 2022-03-09 2023-09-14 Amgen Inc. Optimized transfection protocol
WO2023175022A1 (en) 2022-03-16 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat infectious diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5198542A (en) * 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
AU6030990A (en) * 1989-07-07 1991-02-06 E.I. Du Pont De Nemours And Company Soluble human b-cell interleukin-1 receptor

Also Published As

Publication number Publication date
DE69132937T2 (de) 2002-09-19
JP3652582B2 (ja) 2005-05-25
NZ238255A (en) 1992-03-26
JP3155024B2 (ja) 2001-04-09
ES2172502T3 (es) 2002-10-01
IE911771A1 (en) 1991-12-18
WO1991018982A1 (en) 1991-12-12
JP2000336039A (ja) 2000-12-05
IL98205A0 (en) 1992-06-21
EP0460846A1 (en) 1991-12-11
AU651596B2 (en) 1994-07-28
ATE213743T1 (de) 2002-03-15
DK0460846T3 (da) 2002-06-10
EP0460846B1 (en) 2002-02-27
AU7908191A (en) 1991-12-31
JPH0767651A (ja) 1995-03-14
DE69132937D1 (de) 2002-04-04
US20030060616A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
AU651596B2 (en) Type II interleukin-1 receptors
US5350683A (en) DNA encoding type II interleukin-1 receptors
IE83679B1 (en) Type II interleukin-1 receptors
AU670253B2 (en) Receptor for oncostatin M and leukemia inhibitory factor
AU647566B2 (en) Leukemia inhibitory factor receptors
US5869286A (en) Receptor that binds IL-17
US6355779B1 (en) Cytokine designated 4-1BB ligand antibodies and human receptor that binds thereto
AU646695B2 (en) Isolated viral protein cytokine antagonists
WO1994026290A1 (en) Cytokine designated 4-1bb ligand and human receptor that binds thereto
CA2188279C (en) Interleukin-15 receptors
US7273843B2 (en) Methods of treating allergy by administering interleukin-17 receptor
EP0528928B1 (en) Interleukin-4 binding protein-gamma
IE911108A1 (en) Isolated Viral Protein Cytokine Antagonists

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired